Literature DB >> 15259074

KAI1 gene expression in colonic carcinoma and its clinical significances.

De-Hua Wu1, Li Liu, Long-Hua Chen, Yan-Qing Ding.   

Abstract

AIM: To investigate KAI1 gene expression in the progression of human colonic carcinoma and its clinical significances.
METHODS: KAI1 expression was detected by in situ hybridization and immunohistochemistry in the 4 established cell lines of colorectal carcinoma with different metastatic potentials, and in 80 specimens of colonic carcinoma, 21 colonic carcinoma specimens with lymphatic metastasis and 20 controls of normal colonic mucosa.
RESULTS: The expressions of KAI1 in HT29 and SW480 cell lines were higher than those in LoVo and SW620. The expression of KAI1 gene was significantly higher in colorectal carcinoma compared with normal colonic mucosa and lymphatic metastasis (chi(2)=46.838, P<0.01). The expression of KAI1 gene had no relationship with histological grade. The KAI1 expressions in Dukes A and B carcinoma were higher at both mRNA and protein levels compared to Dukes C carcinoma (chi(2)=16.061, P<0.05). The expression of KAI1 in colonic carcinoma specimens with lymphatic metastasis was almost lost. The results of in situ hybridization were in concordance with immunohistochemistry.
CONCLUSION: KAI1 is highly related to the metastasis of colonic carcinoma and may be a useful indicator of metastasis in colonic carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15259074      PMCID: PMC4723408          DOI: 10.3748/wjg.v10.i15.2245

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  Integrin alpha3 expression as a prognostic factor in colon cancer: association with MRP-1/CD9 and KAI1/CD82.

Authors:  Hiroki Hashida; Arimichi Takabayashi; Takahiro Tokuhara; Toshihiko Taki; Keiichi Kondo; Nobuoki Kohno; Yoshio Yamaoka; Masayuki Miyake
Journal:  Int J Cancer       Date:  2002-02-01       Impact factor: 7.396

2.  NM23 gene product expression does not predict lymph node metastases or survival in young patients with colorectal cancer.

Authors:  S D Heys; N Langlois; I C Smith; L G Walker; O Eremin
Journal:  Oncol Rep       Date:  1998 May-Jun       Impact factor: 3.906

3.  KAI1/CD82 expression as a prognosic factor in sporadic colorectal cancer.

Authors:  T Muneyuki; M Watanabe; M Yamanaka; T Shiraishi; S Isaji
Journal:  Anticancer Res       Date:  2001 Sep-Oct       Impact factor: 2.480

4.  Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma.

Authors:  F S Liu; J T Dong; J T Chen; Y T Hsieh; E S Ho; M J Hung
Journal:  Gynecol Oncol       Date:  2000-07       Impact factor: 5.482

5.  KAI1 metastasis suppressor gene is frequently down-regulated in cervical carcinoma.

Authors:  F S Liu; J T Chen; J T Dong; Y T Hsieh; A J Lin; E S Ho; M J Hung; C H Lu
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

6.  Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation.

Authors:  M Ono; K Handa; D A Withers; S Hakomori
Journal:  Cancer Res       Date:  1999-05-15       Impact factor: 12.701

7.  Differential expression of metastasis-associated genes in papilla of vater and pancreatic cancer correlates with disease stage.

Authors:  H Friess; X Z Guo; A A Tempia-Caliera; A Fukuda; M E Martignoni; A Zimmermann; M Korc; M W Büchler
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

8.  Genomic organization of the human KAI1 metastasis-suppressor gene.

Authors:  J T Dong; W B Isaacs; J C Barrett; J T Isaacs
Journal:  Genomics       Date:  1997-04-01       Impact factor: 5.736

9.  NM23 expression as prognostic factor in colorectal carcinoma.

Authors:  A Forte; A D'Urso; L S Gallinaro; G Lo Storto; G Soda; D Bosco; M Bezzi; F Vietri; V Beltrami
Journal:  G Chir       Date:  2002-03

10.  NM23-H1 immunostaining is inversely associated with tumour staging but not overall survival or disease recurrence in colorectal carcinomas.

Authors:  P Y Cheah; X Cao; K W Eu; F Seow-Choen
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

View more
  7 in total

1.  Down-regulation of the metastasis suppressor protein KAI1/CD82 correlates with occurrence of metastasis, prognosis and presence of HPV DNA in human penile squamous cell carcinoma.

Authors:  C Protzel; C Kakies; B Kleist; M Poetsch; J Giebel
Journal:  Virchows Arch       Date:  2008-02-28       Impact factor: 4.064

2.  Correlation of KAI1, CD133 and vasculogenic mimicry with the prediction of metastasis and prognosis in hepatocellular carcinoma.

Authors:  Jing Xu; Yu Zhang; Yichao Wang; Xiaoying Tao; Lili Cheng; Shiwu Wu; Yisheng Tao
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

3.  Clinicopathological significance of cancer stem cells marked by CD133 and KAI1/CD82 expression in laryngeal squamous cell carcinoma.

Authors:  Lan Yu; Lei Zhou; Shiwu Wu; Xiaomeng Gong; Zhenzhong Feng; Li Ma; Bo Zhu; Nan Yao; Danna Wang; Huiming Dong
Journal:  World J Surg Oncol       Date:  2014-04-24       Impact factor: 2.754

4.  The expression of metastasis-associated in colon cancer-1 and KAI1 in gastric adenocarcinoma and their clinical significance.

Authors:  Guoyu Lu; Lei Zhou; Xiaohua Zhang; Bo Zhu; Shiwu Wu; Wenqing Song; Xiaomeng Gong; Danna Wang; Yanyan Tao
Journal:  World J Surg Oncol       Date:  2016-10-28       Impact factor: 2.754

5.  Differential tumor biological role of the tumor suppressor KAI1 and its splice variant in human breast cancer cells.

Authors:  Julia Miller; Tobias F Dreyer; Anne Sophie Bächer; Eva-Kathrin Sinner; Christine Heinrich; Anke Benge; Eva Gross; Sarah Preis; Jan Rother; Anthony Roberts; Gabriele Nelles; Tzenka Miteva; Ute Reuning
Journal:  Oncotarget       Date:  2018-01-05

Review 6.  TSPAN8 as a Novel Emerging Therapeutic Target in Cancer for Monoclonal Antibody Therapy.

Authors:  Kyun Heo; Sukmook Lee
Journal:  Biomolecules       Date:  2020-03-03

7.  Aberrant expression of CD133 and CD82 in patients with pediatric acute lymphoblastic leukemia and the clinical significance.

Authors:  Hongyan Ji; Li Chen; Yunpeng Dai; Xiaojun Sun; Xiuli Li; Qi Wang; Daoxin Ma; Dongdong Du; Ping Zhao; Yulin Wang
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.